Two-drug combo for advanced lung cancer with high PD-L1
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced (stage IIIB/IIIC/IV) non-small cell lung cancer.
- Your tumor does not have an EGFR or ALK mutation.
- Your PD-L1 score is 1% or higher (for the main part of the study).
- You have not had immunotherapy before (for the main part of the study).
- You are in good enough health to walk and take care of yourself (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
This trial tests a combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced lung cancer that stopped responding to a PD-1 inhibitor. The goal is to see if this new triple therapy can help shrink tumors or slow down the cancer.
This trial tests whether continuing a PD-1 inhibitor (a type of immunotherapy) after surgery can help people with non-small cell lung cancer who did not have a complete response to initial chemotherapy plus immunotherapy before surgery. It aims to improve outcomes for those whose tumors still had significant cancer cells after the first treatment.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.